Main Menu Home Anxiety Disorders About Us Resources Disclaimer Random Articles Panic Disorder Often Undertreated Depression Takes Financial Toll in Florida Focus On Stress-Related Infertility In Rats And Humans By The European Society Of Human... Epidemiology of Social Phobia in Later Life What Is Anxiety And How To Treat It Neurocrine Biosciences Announces Initiation Of Phase II Clinical Trials With CRF1 Antagonist For... Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that under the collaboration between Neurocrine and GlaxoSmithKline (GSK), GSK has initiated Phase II "proof of concept" clinical trials with a lead Corticotropin Releasing Factor R1 (CRF1) receptor antagonist compound for two indications, social anxiety disorder (SocAD) and irritable bowel syndrome (IBS). [click link for full article] Read more at: http://www.medicalnewstoday.com/medicalnews.php?newsid=59541&nfid=crss.   < Prev   Next > [ Back ] Related Resources Womens Health | Family Health | Diet Weight Loss | Beauty Fashion | Self Improvement | Relieve stress instantly

Attack Panic is a resource for panic and anxiety disorders. Information on these pages is (C) AttackPanic.com. Disclaimer.